Skip to main content
Top
Published in: Malaria Journal 1/2009

Open Access 01-12-2009 | Research

Determination of the Plasmodium vivax relapse pattern in Camopi, French Guiana

Authors: Matthieu Hanf, Aurélia Stéphani, Célia Basurko, Mathieu Nacher, Bernard Carme

Published in: Malaria Journal | Issue 1/2009

Login to get access

Abstract

Background

Malaria is a major public health problem in French Guiana, where Plasmodium vivax has become the dominant malaria species since 2000. As in others endemic areas, it is important to specify the pattern of vivax malaria relapses and to try to discriminate efficiently re-infections from relapses.

Methods

This study was conducted in children born between January 1, 2001 and December 31, 2008 in Camopi, an Amerindian village located in the Amazon forest (n = 325), using an open cohort design. Primary and secondary attack rates of P. vivax were calculated using survival analysis. With the difference between the primary and secondary rates, this study aimed to estimate indirectly P. vivax relapse rate and evaluate its time evolution.

Results

Of the 1042 malaria attacks recorded, 689 (66%) were due to P. vivax (without mixed infection). One hundred and fifty one children had their primary attack with P. vivax and 106 had their two first attacks with P. vivax. In the absence of primaquine treatment, it was shown that P. vivax relapses mainly occurred during the first three months after the first attack. Thirty percent of children never had a relapse, 42% had a relapse before the first month after primary attack, 59% before the second month and 63% before the third month.

Conclusion

This study confirmed that the relapse pattern in Camopi was compatible with the pattern described for the P. vivax Chesson (tropical) strain. In addition, due to the relapse rate time evolution, a simple arbitrary classification rule could be constructed: before 90 days after the primary attack, the secondary attack is a relapse; after 90 days, it is a re-infection. Adapted management of malaria cases based on these results could be devised.
Appendix
Available only for authorised users
Literature
1.
go back to reference Mendis K, Sina BJ, Marchesini P, Carter R: The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001, 64: 97-106.PubMed Mendis K, Sina BJ, Marchesini P, Carter R: The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001, 64: 97-106.PubMed
3.
go back to reference Yeom JS, Ryu SH, Oh S, Lee WJ, Kim TS, Kim KH, Kim YA, Ahn SY, Cha JE, Park JW: Status of Plasmodium vivax malaria in the Republic of Korea during 2001-2003. Am J Trop Med Hyg. 2005, 73: 604-608.PubMed Yeom JS, Ryu SH, Oh S, Lee WJ, Kim TS, Kim KH, Kim YA, Ahn SY, Cha JE, Park JW: Status of Plasmodium vivax malaria in the Republic of Korea during 2001-2003. Am J Trop Med Hyg. 2005, 73: 604-608.PubMed
4.
go back to reference Sumawinata IW, Bernadeta , Leksana B, Sutamihardja A, Purnomo , Subianto B, Sekartuti , Fryauff DJ, Baird JK: Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg. 2003, 68: 416-420.PubMed Sumawinata IW, Bernadeta , Leksana B, Sutamihardja A, Purnomo , Subianto B, Sekartuti , Fryauff DJ, Baird JK: Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg. 2003, 68: 416-420.PubMed
5.
go back to reference Baird JK: Neglect of Plasmodium vivax malaria. Trends in Parasitology. 2007, 23: 533-539. 10.1016/j.pt.2007.08.011.CrossRefPubMed Baird JK: Neglect of Plasmodium vivax malaria. Trends in Parasitology. 2007, 23: 533-539. 10.1016/j.pt.2007.08.011.CrossRefPubMed
6.
go back to reference Carme B: Substantial increase of malaria in inland areas of eastern French Guiana. Trop Med Int Health. 2005, 10: 154-159. 10.1111/j.1365-3156.2004.01365.x.CrossRefPubMed Carme B: Substantial increase of malaria in inland areas of eastern French Guiana. Trop Med Int Health. 2005, 10: 154-159. 10.1111/j.1365-3156.2004.01365.x.CrossRefPubMed
7.
go back to reference Abeku TA, van Oortmarssen GJ, Borsboom G, de Vlas SJ, Habbema JD: Spatial and temporal variations of malaria epidemic risk in Ethiopia: factors involved and implications. Acta Trop. 2003, 87: 331-340. 10.1016/S0001-706X(03)00123-2.CrossRefPubMed Abeku TA, van Oortmarssen GJ, Borsboom G, de Vlas SJ, Habbema JD: Spatial and temporal variations of malaria epidemic risk in Ethiopia: factors involved and implications. Acta Trop. 2003, 87: 331-340. 10.1016/S0001-706X(03)00123-2.CrossRefPubMed
8.
go back to reference Tian L, Bi Y, Ho SC, Liu W, Liang S, Goggins WB, Chan EY, Zhou S, Sung JJ: One-year delayed effect of fog on malaria transmission: a time-series analysis in the rain forest area of Mengla County, south-west China. Malar J. 2008, 7: 110-10.1186/1475-2875-7-110.PubMedCentralCrossRefPubMed Tian L, Bi Y, Ho SC, Liu W, Liang S, Goggins WB, Chan EY, Zhou S, Sung JJ: One-year delayed effect of fog on malaria transmission: a time-series analysis in the rain forest area of Mengla County, south-west China. Malar J. 2008, 7: 110-10.1186/1475-2875-7-110.PubMedCentralCrossRefPubMed
9.
go back to reference Adak T, Sharma VP, Orlov VS: Studies on the Plasmodium vivax relapse pattern in Delhi, India. Am J Trop Med Hyg. 1998, 59: 175-179.PubMed Adak T, Sharma VP, Orlov VS: Studies on the Plasmodium vivax relapse pattern in Delhi, India. Am J Trop Med Hyg. 1998, 59: 175-179.PubMed
10.
go back to reference Prasad RN, Virk KJ, Sharma VP: Relapse/reinfection patterns of Plasmodium vivax infection: a four year study. Southeast Asian J Trop Med Public Health. 1991, 22: 499-503.PubMed Prasad RN, Virk KJ, Sharma VP: Relapse/reinfection patterns of Plasmodium vivax infection: a four year study. Southeast Asian J Trop Med Public Health. 1991, 22: 499-503.PubMed
11.
go back to reference Craig AA, Kain KC: Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. J Infect Dis. 1996, 174: 373-379.CrossRefPubMed Craig AA, Kain KC: Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. J Infect Dis. 1996, 174: 373-379.CrossRefPubMed
12.
go back to reference Kirchgatter K, del Portillo HA: Molecular analysis of Plasmodium vivax relapses using the MSP1 molecule as a genetic marker. J Infect Dis. 1998, 177: 511-515. 10.1086/517389.CrossRefPubMed Kirchgatter K, del Portillo HA: Molecular analysis of Plasmodium vivax relapses using the MSP1 molecule as a genetic marker. J Infect Dis. 1998, 177: 511-515. 10.1086/517389.CrossRefPubMed
13.
go back to reference Veron V, Legrand E, Yrinesi J, Volney B, Simon S, Carme B: Genetic diversity of msp3alpha and msp1_b5 markers of Plasmodium vivax in French Guiana. Malar J. 2009, 8: 40-10.1186/1475-2875-8-40.PubMedCentralCrossRefPubMed Veron V, Legrand E, Yrinesi J, Volney B, Simon S, Carme B: Genetic diversity of msp3alpha and msp1_b5 markers of Plasmodium vivax in French Guiana. Malar J. 2009, 8: 40-10.1186/1475-2875-8-40.PubMedCentralCrossRefPubMed
14.
go back to reference Carme B, Lecat J, Lefebvre P: Le Paludisme en Guyane dans le foyer de l'Oyapock. Incidence des accès palustres chez les amérindiens de Camopi. Med Trop (Marseille). 2005, 65: 149-154. Carme B, Lecat J, Lefebvre P: Le Paludisme en Guyane dans le foyer de l'Oyapock. Incidence des accès palustres chez les amérindiens de Camopi. Med Trop (Marseille). 2005, 65: 149-154.
15.
go back to reference Hustache S, Nacher M, Djossou F, Carme B: Malaria risk factors in amerindians children in French Guiana. Am J Trop Med Hyg. 2007, 76: 619-625.PubMed Hustache S, Nacher M, Djossou F, Carme B: Malaria risk factors in amerindians children in French Guiana. Am J Trop Med Hyg. 2007, 76: 619-625.PubMed
16.
go back to reference Chongsuvivatwong V: Analysis of epidemiological data using R and Epicalc. Edited by: McNeil. 2007, Special Programme for Research & Training in Tropical Diseases (TDR) Chongsuvivatwong V: Analysis of epidemiological data using R and Epicalc. Edited by: McNeil. 2007, Special Programme for Research & Training in Tropical Diseases (TDR)
17.
go back to reference Ehrman FC, Ellis JM, Young MD: Plasmodium vivax Chesson strain. Science. 1945, 101: 377-10.1126/science.101.2624.377.CrossRefPubMed Ehrman FC, Ellis JM, Young MD: Plasmodium vivax Chesson strain. Science. 1945, 101: 377-10.1126/science.101.2624.377.CrossRefPubMed
18.
go back to reference Molineaux L, Storey J, Cohen JE, Thomas A: A longitudinal study of human malaria in the West African Savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. Am J Trop Med Hyg. 1980, 29: 725-737.PubMed Molineaux L, Storey J, Cohen JE, Thomas A: A longitudinal study of human malaria in the West African Savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. Am J Trop Med Hyg. 1980, 29: 725-737.PubMed
19.
go back to reference Mason J: Patterns of Plasmodium vivax recurrence in a high-incidence coastal area of El Salvador, C. A. Am J Trop Med Hyg. 1975, 24: 581-585.PubMed Mason J: Patterns of Plasmodium vivax recurrence in a high-incidence coastal area of El Salvador, C. A. Am J Trop Med Hyg. 1975, 24: 581-585.PubMed
Metadata
Title
Determination of the Plasmodium vivax relapse pattern in Camopi, French Guiana
Authors
Matthieu Hanf
Aurélia Stéphani
Célia Basurko
Mathieu Nacher
Bernard Carme
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2009
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-8-278

Other articles of this Issue 1/2009

Malaria Journal 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.